News Daily News Even With Optimized GDMT, HFrEF Prognosis Remains Dire Michael O'Riordan January 30, 2026
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Daily News FDA Approves Vericiguat for High-risk Patients With HF Michael O'Riordan January 20, 2021